Anthrax is a severe infectious disease caused by spores of a
gram-positive bacterium called Bacillus anthracis. It generally
infects through four routes viz. the lungs, the intestines, the skin,
and injectable. Anthrax affects both humans and animals, especially
ruminants such as cattle, sheep, goats, and horses. It does not
easily spread from one person to another. Signs and symptoms of
anthrax vary depending on the type of infection. Cutaneous anthrax,
gastrointestinal anthrax, inhalation anthrax, and injection anthrax
have different symptoms. Common symptoms of cutaneous anthrax include
rashes that are swollen, sore, and itchy. Nausea, abdominal pain,
loss of appetite, vomiting, fever, bloody diarrhea, swollen neck,
headache, and difficulty swallowing are most common signs and
symptoms of gastrointestinal anthrax. Shortness of breath, coughing
up blood, painful swallowing, mild chest discomfort, and nausea are
symptoms of inhalation anthrax. Multiple organ failure, meningitis,
and redness at the area of injection are the most common signs and
symptoms of injection anthrax. Currently, two key methods are
available to diagnose anthrax globally that utilizes the
presence/absence of either antibodies or toxins in the patient’s
blood sample. Moreover, healthcare specialists also recommended to
use direct tests for diagnosing the presence of Bacillus anthracis in
the sample (skin lesion swab, respiratory secretions, blood, and
spinal fluid). Cell-free PA vaccines and live vaccines are available
in the market for Anthrax vaccines.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36116
The global anthrax vaccines market is expanding significantly, due to
increasing prevalence of the disease. Increased eating of undercooked
or raw meat from infected animals drives the anthrax vaccines market.
Increase in Industrial or manufacturing processing of contaminated
materials such as hides and hair wool would also augment the market.
Low rate of voluntary screening for the anthrax disease is a major
restraint for the market. Awareness about anthrax diagnostic tests is
extremely low in countries in Africa. Hence, companies are facing
challenges with regard to market penetration in Africa. Moreover,
several low- and middle-income countries in the sub-region depend on
government grants for the provision of rapid diagnostic tests in the
event of an epidemic. Therefore, direct reach to customers is weaker
in these countries. These factors hamper the market in Africa.
The global anthrax vaccines market can be segmented based on vaccine
type, application, distribution channel, and region. In terms of
vaccine type, the market can be categorized into cell-free PA
vaccines and live vaccines. Based on application, the anthrax
vaccines market can be segmented into human use and animal use. In
terms of distribution channel, the market can be classified into
hospital pharmacies, retail pharmacies, and online pharmacies. In
terms of revenue, the hospital pharmacies segment held a significant
share of the global anthrax vaccines market in 2016.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=36116
Based on region, the global anthrax vaccines market can be segmented
into North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa. North America is the leading market for anthrax
vaccines. In terms of revenue, the U.S. holds a major share of the
market in North America. The market in Europe is expanding rapidly,
due to increasing patient population, especially in the U.K. and
Germany. The markets in Asia Pacific and Latin America are projected
to expand significantly in the near future. Developing economies such
as China and India are anticipated to contribute to growth of the
market in Asia Pacific between 2017 and 2025, owing to improved
health care infrastructure, economic growth, increase in the number
of insurance payers, growth of the private health care sector, and
increase in awareness in these countries.
Key players operating in the global anthrax vaccines market are Merck
& Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene,
Inc., Biogenesis Bago S.A., Porton Biopharma Limited, Colorado Serum,
and Merial (a Sanofi Compayny).
Report Overview @
https://www.transparencymarketresearch.com/anthrax-vaccines-market.html
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment